The endocrine disrupting potential of monosodium glutamate (MSG) on secretion of the glucagon-like peptide-1 (GLP-1) gut hormone and GLP-1 receptor interaction

Toxicology Letters

Volumn 265, Issue , 2017, Pages 97-105

  Shannon, Maeve ^a   Green, Brian ^a   Willars, Gary ^b   Wilson, Jodie ^a   Matthews, Natalie ^a   Lamb, Joanna ^a   Gillespie, Anna ^a   Connolly, Lisa ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Diabetes; GLP 1; High content analysis; In vitro bioassays; Monosodium glutamate; Obesity

Indexed keywords

ENDOCRINE DISRUPTOR; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTAMATE SODIUM;

ARTICLE; BIOASSAY; CONTENT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENTEROENDOCRINE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; OBESITY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; U2OS CELL LINE; ANIMAL; CELL CULTURE TECHNIQUE; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; MOUSE; SECRETION (PROCESS); TIME FACTOR;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CELL SURVIVAL; ENDOCRINE DISRUPTORS; ENTEROENDOCRINE CELLS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INTESTINAL MUCOSA; MICE; OBESITY; SODIUM GLUTAMATE; TIME FACTORS;

EID: 84999792421     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2016.11.015     Document Type: Article

References (50)

1. Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A., Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15 (1995), 961–973.
2. Baggio, L., Drucker, D., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
3. Beucher, A., Gjernes, E., Collin, C., Courtney, M., Meunier, A., Collombat, P., The homeodomain-containing transcription factors Arx and Pax4 control enteroendocrine subtype specification in mice. PLoS One, 7(5), 2012, e36449.
4. Buse, J., Nauck, M., Forst, T., Sheu, W., Shenouda, S., Heilmann, C., et al. Exenatide once weeklyversus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381 (2013), 117–124.
5. COT, 2013. Scoping paper on the obesogen hypothesis (pp. 1–23). Available from: https://cot.food.gov.uk/sites/default/files/cot/tox2013.pdf (Accessed 12.06.16.).
6. Clough, R., Ararich, P., Sladek, C., Monosodium glutamate neurotoxicity: a sex-specific impairment of blood pressure but not vasopressin in developing rats. Brain Res. Bull. 17:1 (1986), 51–58.
7. Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Makhoul, N.J., Bakheet, R., Al-Mohanna, F.A., Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J. Lipid Res. 50 (2009), 1521–1537.
8. D'Alessio, D.A., Vogel, R., Prigeon, R., Laschansky, E., Koerker, D., Eng, J., Ensinck, J.W., Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Investig. 97:1 (1996), 133–138.
9. Drucker, D.J., The biology of incretin hormones. Cell Metab. 3:3 (2006), 153–165.
10. Edwards, C., Todd, J., Mahmoudi, M., Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48 (1999), 86–93.
11. Elliott, R.M., Morgan, L.M., Tredger, J.A., Deacon, S., Wright, J., Marks, V., Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man—acute postprandial and 24-H secretion patterns. J. Endocrinol. 138 (1993), 159–166.
12. Elmore, S., Apoptosis: a review of programmed cell death. Toxocol. Pathol. 35:4 (2007), 495–516.
13. Gillespie, A.L., Calderwood, D., Hobson, L., Green, B.D., Whey proteins have beneficial effects on intestinal enteroendocrine cells stimulating cell growth and increasing the production and secretion of incretin hormones. Food Chem. 189 (2015), 120–128.
14. Green, B.D., Irwin, N., Gault, V.A., Bailey, C.J., O'Harte, F.P.M., Flatt, P.R., Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J. Endocrinol. 185 (2005), 307–317.
15. Habib, A.M., Richards, P., Cairns, L.S., Rodger, G.J., Bannon, C.A., Parker, H.E., Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153:7 (2012), 3054–3065.
16. Hand, K.V., Giblin, L., Green, B.D., Hormone profiling in a novel enteroendocrine cell line pGIP/neo: STC-1. Metabolism 61:12 (2012), 1683–1686.
17. Hansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jorgensen, P.N., Holst, J.J., Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am. J. Physiol. Endocrinol. Metab. 278 (2000), E1010–E1018.
18. He, K., Zhao, L., Daviglus, M.L., Dyer, A.R., Van Horn, L., Garside, D., Zhu, L., Guo, D., Wu, Y., Zhou, B., Stamler, J., Association of monosodium glutamate intake with overweight in Chinese adults: the INTERMAP study. Obesity 16 (2008), 1875–1880.
19. He, K., Du, S., Xun, P., Sharma, S., Wang, H., Zhai, F., Popkin, B., Consumption of monosodium glutamate in relation to incidence of overweight in Chinese adults: China Health and Nutrition Survey (CHNS). Am. J. Clin. Nutr. 1–3 (2011), 1–3.
20. Hirata, E., Andrade, I.S., Vaskevicius, P., Dolnikoff, M.S., Monosodium glutamate (MSG)-obese rats develop glucose intolerance and insulin resistance to peripheral glucose uptake. Braz. J. Med. Biol. Res. 30:5 (1997), 671–674.
21. Holtcamp, W., Obesogens: an environmental link to obesity. Environ. Health Perspect. 120:2 (2012), a62–a68.
22. Hosaka, H., Kusano, M., Zai, H., Monosodium glutamate stimulates secretion of glucagon-like peptide-1 and reduces postprandial glucose after a lipid-containing meal. Aliment. Pharmacol. Ther. 36:1 (2012), 95–903.
23. Husarova, V., Ostatnikova, D., Monosodium glutamate toxic effects and their implications for human intake: a review. JMED Res. 2013 (2013), 1–12.
24. Insawang, T., Selmi, C., Cha'on, U., Pethlert, S., Yongvanit, P., Areejitranusorn, P., Hammock, B.D., Monosodium glutamate (MSG) intake is associated with the prevalence of metabolic syndrome in a rural Thai population. Nutr. Metab., 9(1), 2012, 50.
25. Iwase, M., Yamamoto, M., Iino, K., Ichikawa, K., Shinohara, N., Yoshinari, M., Fujishima, M., Obesity induced by neonatal monosodium glutamate treatment in spontaneously hypertensive rats: an animal model of multiple risk factors. Hypertens. Res. 21:1 (1998), 1–6.
26. Jafri, L., Saleem, S., Calderwood, D., Gillespie, A., Mirza, B., Green, B.D., Naturally-occurring TGR5 agonists modulating glucagon-like peptide-1 biosynthesis and secretion. Peptides 78 (2016), 51–58.
27. Kendig, D., Bala, V., Murthy, K., Grider, J., Neurotensin partially mediates the monosodium glutamate (MSG)-induced peristaltic reflex. FASEB J. 29:Suppl. 1 (2015), 850–851.
28. Kolligs, F., Fehmann, H., Goke, R., Goke, B., Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44 (2002), 16–19.
29. l-cells. Am. J. Physiol. Endocrinol. Metab. 305:2 (2013), E161–E170.
30. Lahlou, H., Guillermet, J., Hortala, M., Vernejoul, F., Pyronnet, S., Bousquet, C., Susini, C., Molecular signaling of somatostatin receptors. Ann. N. Y. Acad. Sci. 1014 (2004), 121–131 Gastroenteropancreatic Neuroendocrine Tumor Disease: Molecular and Cell Biological Aspects.
31. Macdonald, P.E., El-kholy, W., Riedel, M.J., Salapatek, A.M.F., Light, P.E., Wheeler, M.B., The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 (2002), S434–S442.
32. Mercola, 2009. MSG: Is This Silent Killer Lurking in Your Kitchen Cabinets. Available from: http://articles.mercola.com/sites/articles/archive/2009/04/21/msg-is-this-silent-killer-lurking-in-your-kitchen-cabinets.aspx (Accessed 12.06.16.).
33. Miskowiak, B., Limanowski, A., Partyka, M., Effect of perinatal administration of monosodium glutamate (MSG) on the reproductive system of the male rat. Endokrynologia Polska 44 (1993), 497–505.
34. Miyata, M., Kurogi, M., Oda, M., Saitoh, O., Effect of five taste ligands on the release of CCK from an enteroendocrine cell line, STC-1. Biomed. Res. 35:2 (2014), 171–176.
35. Nakanishi, Y., Tsuneyama, K., Fujimoto, M., Salunga, T.L., Nomoto, K., An, J.L., Takano, Y., Iizuka, S., Nagata, M., Suzuki, W., Shimada, T., Aburada, M., Nakano, M., Selmi, C., Gershwin, M.E., Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30 (2008), 42–50.
36. Noerklit, S., Wismann, P., Rye, C., Kulahin, N., Iversen, H., Arevad, K., Waldhoer, M., Molecular and cellular endocrinology real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol. Cell. Endocrinol. 382:2 (2014), 938–949.
37. Norbury, C.J., Hickson, I.D., Cellular responses to DNA damage. Annu. Rev. Pharmacol. Toxicol. 41 (2001), 367–401.
38. O'Brien, P., Haskins, J.R., In vitro cytotoxicity assessment. Taylor, D.L., Haskins, J.R., Giuliano, K.A., (eds.) High Content Screening (Methods in Molecular Biology), 2007, Humana Press, NJ, USA, 415–425.
39. Olney, J., Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164:880 (1969), 719–721.
40. Pavlovic, V., Pavlovic, D., Kocic, A., Ascorbic acid modulates monosodium glutamate induced cytotoxicity in rat thymus. Bratisl. Lek. Listy 110:4 (2009), 205–209.
41. Ramshur, E.B., Rull, T.R., Wice, B.M., Novel insulin/GIP co-producing cell lines provide unexpected insights into gut K-cell function in vivo. J. Cell. Physiol. 192 (2002), 339–350.
42. Rask, E., Olsson, T., Soderberg, S., Johnson, O., Seckl, J., Holst, J.J., Ahren, B., Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24 (2001), 1640–1645.
43. Reimann, F., Williams, L., Xavier, G.D., Rutter, G.A., Gribble, F.M., Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 47 (2004), 1592–1601.
44. Scrocchi, L., Brown, T., MacLusky, N., Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. 2 (1996), 1254–1258.
45. Sharpe, R.M., Drake, A.J., Obesogens and obesity—an alternative view?. Obesity (Silver Spring) 21:6 (2013), 1081–1083.
46. Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87 (2010), 4–14.
47. Shi, Z., Taylor, A.W., Yuan, B., Zuo, H., Wittert, G.A., Monosodium glutamate intake is inversely related to the risk of hyperglycemia. Clin. Nutr. 33:5 (2014), 823–828.
48. Svidnicki, P.V., de Carvalho Leite, N., Venturelli, A.C., Camargo, R.L., Vicari, M.R., de Almeida, M.C., Artoni, R.F., Nogaroto, V., Grassiolli, S., Swim training restores glucagon-like peptide-1 insulinotropic action in pancreatic islets from monosodium glutamate-obese rats. Acta Physiol. 209:1 (2013), 34–44.
49. Vilsbøll, T., Krarup, T., Deacon, C.F., Madsbad, S., Holst, J.J., Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001), 609–613.
50. Zeiss, C.J., The apoptosis-necrosis continuum: insights from genetically altered mice. Vet. Pathol. 40:5 (2003), 481–495.